A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Latest Information Update: 22 Dec 2023
At a glance
- Drugs CNP 201 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Cour Pharmaceutical Development
Most Recent Events
- 14 Dec 2023 Status changed from recruiting to discontinued.
- 14 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 14 Jul 2023 Planned primary completion date changed from 30 May 2023 to 30 May 2024.